Ameritas Investment Partners’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $237K | Buy |
5,097
+590
| +13% | +$28.3K | 0.01% | 1295 |
|
|
2026
Q1 | $233K | Hold |
4,507
| – | – | 0.01% | 1180 |
|
|
2025
Q4 | $224K | Hold |
4,507
| – | – | 0.01% | 1188 |
|
|
2025
Q3 | $215K | Sell |
4,507
-746
| -14% | -$30K | 0.01% | 1200 |
|
|
2025
Q2 | $166K | Hold |
5,253
| – | – | 0.01% | 1415 |
|
|
2025
Q1 | $172K | Hold |
5,253
| – | – | 0.01% | 1357 |
|
|
2024
Q4 | $190K | Buy |
5,253
+369
| +8% | +$13K | 0.01% | 1354 |
|
|
2024
Q3 | $152K | Hold |
4,884
| – | – | 0.01% | 1511 |
|
|
2024
Q2 | $131K | Hold |
4,884
| – | – | ﹤0.01% | 1558 |
|
|
2024
Q1 | $167K | Hold |
4,884
| – | – | 0.01% | 1415 |
|
|
2023
Q4 | $141K | Hold |
4,884
| – | – | 0.01% | 1502 |
|
|
2023
Q3 | $135K | Buy |
4,884
+825
| +20% | +$25.1K | 0.01% | 1446 |
|
|
2023
Q2 | $122K | Buy |
4,059
+293
| +8% | +$10.3K | ﹤0.01% | 1460 |
|
|
2023
Q1 | $136K | Hold |
3,766
| – | – | 0.01% | 1319 |
|
|
2022
Q4 | $155K | Hold |
3,766
| – | – | 0.01% | 1307 |
|
|
2022
Q3 | $127K | Hold |
3,766
| – | – | 0.01% | 1330 |
|
|
2022
Q2 | $108K | Hold |
3,766
| – | – | ﹤0.01% | 1457 |
|
|
2022
Q1 | $122K | Hold |
3,766
| – | – | ﹤0.01% | 1506 |
|
|
2021
Q4 | $110K | Hold |
3,766
| – | – | ﹤0.01% | 1621 |
|
|
2021
Q3 | $100K | Sell |
3,766
-357
| -9% | -$9.58K | ﹤0.01% | 1696 |
|
|
2021
Q2 | $127K | Hold |
4,123
| – | – | ﹤0.01% | 1575 |
|
|
2021
Q1 | $108K | Sell |
4,123
-295
| -7% | -$8.25K | ﹤0.01% | 1620 |
|
|
2020
Q4 | $111K | Hold |
4,418
| – | – | 0.01% | 1518 |
|
|
2020
Q3 | $92K | Hold |
4,418
| – | – | ﹤0.01% | 1480 |
|
|
2020
Q2 | $105K | Hold |
4,418
| – | – | 0.01% | 1382 |
|
|
2020
Q1 | $79K | Buy |
4,418
+336
| +8% | +$7.06K | ﹤0.01% | 1402 |
|
|
2019
Q4 | $97K | Hold |
4,082
| – | – | ﹤0.01% | 1536 |
|
|
2019
Q3 | $112K | Hold |
4,082
| – | – | 0.01% | 1401 |
|
|
2019
Q2 | $135K | Hold |
4,082
| – | – | 0.01% | 1305 |
|
|
2019
Q1 | $143K | Hold |
4,082
| – | – | 0.01% | 1241 |
|
|
2018
Q4 | $136K | Hold |
4,082
| – | – | 0.01% | 1188 |
|
|
2018
Q3 | $206K | Hold |
4,082
| – | – | 0.01% | 1070 |
|
|
2018
Q2 | $244K | Buy |
4,082
+31
| +0.8% | +$1.61K | 0.01% | 966 |
|
|
2018
Q1 | $186K | Hold |
4,051
| – | – | 0.01% | 1119 |
|
|
2017
Q4 | $161K | Hold |
4,051
| – | – | 0.01% | 1211 |
|
|
2017
Q3 | $185K | Hold |
4,051
| – | – | 0.01% | 1106 |
|
|
2017
Q2 | $175K | Hold |
4,051
| – | – | 0.01% | 1133 |
|
|
2017
Q1 | $127K | Buy |
+4,051
| New | +$109K | 0.01% | 1292 |
|
Other funds holding SUPN
AC
NAMI
SIMG
Ameritas Investment Partners's SUPN Position: Q2 2026 in Review
Ameritas Investment Partners increased its Supernus Pharmaceuticals (SUPN) stake by 13% in Q2 2026, buying an estimated $28.3K and bringing the position to 5,097 shares worth $237K. The position accounts for 0.01% of the portfolio, ranked #1295.
Ameritas Investment Partners first reported a position in SUPN in Q1 2017 and has held it in 38 quarters since. The position peaked at $244K in Q2 2018. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.
- Ameritas Investment Partners held 5,097 shares of Supernus Pharmaceuticals worth $237K as of Q2 2026.
- Ameritas Investment Partners bought 590 Supernus Pharmaceuticals shares in Q2 2026, an estimated $28.3K.
- Supernus Pharmaceuticals made up 0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #1295 holding.
- Ameritas Investment Partners first reported a position in Supernus Pharmaceuticals in Q1 2017 and has held it in 38 quarters since.
- Ameritas Investment Partners's Supernus Pharmaceuticals position peaked at $244K in Q2 2018.
- 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.
Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.